Page 1 | Search Results | Clinical Cancer Research | American Association for Cancer Research

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Clin Cancer Res (2024) 30 (17): 3812–3823.

https://doi.org/10.1158/1078-0432.CCR-23-3981

Published: 03 September 2024

View article titled, Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

Includes: Supplementary data

Journal Articles

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer

Komal Jhaveri, Joshua Z. Drago, Payal Deepak Shah, Rui Wang, Fresia Pareja, Fanni Ratzon, Alexia Iasonos, Sujata Patil, Neal Rosen, Monica N. Fornier, Nancy T. Sklarin, Sarat Chandarlapaty, Shanu Modi

Clin Cancer Res (2021) 27 (14): 3867–3875.

https://doi.org/10.1158/1078-0432.CCR-21-0047

Published: 15 July 2021

View article titled, A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer

Includes: Supplementary data

Journal Articles

KRAS^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Clin Cancer Res (2021) 27 (9): 2604–2612.

https://doi.org/10.1158/1078-0432.CCR-20-4772

Published: 01 May 2021

View article titled, KRASG12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Includes: Supplementary data

Journal Articles

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Clin Cancer Res (2021) 27 (8): 2226–2235.

https://doi.org/10.1158/1078-0432.CCR-20-4189

Published: 15 April 2021

View article titled, Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Includes: Supplementary data

Journal Articles

Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer

Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna R. Parikh, Hideaki Bando, Emily E. Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire N. Thant, Elisa de Stanchina, Neal Rosen, Ryan B. Corcoran, Takayuki Yoshino, Zhan Yao, Hiromichi Ebi

Clin Cancer Res (2019) 25 (23): 7089–7097.

https://doi.org/10.1158/1078-0432.CCR-19-2004

Published: 02 December 2019

View article titled, Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer

Includes: Supplementary data

Journal Articles

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Rona Yaeger, Andrea Cercek, Eileen M. O'Reilly, Diane L. Reidy, Nancy Kemeny, Tamar Wolinsky, Marinela Capanu, Marc J. Gollub, Neal Rosen, Michael F. Berger, Mario E. Lacouture, Efsevia Vakiani, Leonard B. Saltz

Clin Cancer Res (2015) 21 (6): 1313–1320.

https://doi.org/10.1158/1078-0432.CCR-14-2779

Published: 12 March 2015

View article titled, Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Includes: Supplementary data

Journal Articles

Abstract A22: Role of cap-dependent translation in response to upstream kinase-targeted therapy in colorectal cancer

Qing Ye, Weijia Cai, B. Mark Evers, David Solit, Neal Rosen, Qing-Bai She

Clin Cancer Res (2015) 21 (4_Supplement): A22.

https://doi.org/10.1158/1557-3265.PMS14-A22

Published: 13 February 2015

View article titled, Abstract A22: Role of cap-dependent translation in response to upstream kinase-targeted therapy in colorectal cancer

Journal Articles

PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma

Rita A. Sakr, Britta Weigelt, Sarat Chandarlapaty, Victor P. Andrade, Elena Guerini-Rocco, Dilip Giri, Charlotte K.Y. Ng, Catherine F. Cowell, Neal Rosen, Jorge S. Reis-Filho, Tari A. King

Clin Cancer Res (2014) 20 (9): 2326–2337.

https://doi.org/10.1158/1078-0432.CCR-13-2267

Published: 30 April 2014

View article titled, PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma

Includes: Supplementary data

Journal Articles

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF^V600E/K-Mutated Melanoma

Federica Catalanotti, David B. Solit, Melissa P. Pulitzer, Michael F. Berger, Sasinya N. Scott, Tunc Iyriboz, Mario E. Lacouture, Katherine S. Panageas, Jedd D. Wolchok, Richard D. Carvajal, Gary K. Schwartz, Neal Rosen, Paul B. Chapman

Clin Cancer Res (2013) 19 (8): 2257–2264.

https://doi.org/10.1158/1078-0432.CCR-12-3476

Published: 15 April 2013

View article titled, Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAFV600E/K-Mutated Melanoma

Includes: Supplementary data

Journal Articles

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Sarat Chandarlapaty, Rita A. Sakr, Dilip Giri, Sujata Patil, Adriana Heguy, Monica Morrow, Shanu Modi, Larry Norton, Neal Rosen, Clifford Hudis, Tari A. King

Clin Cancer Res (2012) 18 (24): 6784–6791.

https://doi.org/10.1158/1078-0432.CCR-12-1785

Published: 16 December 2012

View article titled, Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

Includes: Supplementary data

Journal Articles

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Shanu Modi, Alison Stopeck, Hannah Linden, David Solit, Sarat Chandarlapaty, Neal Rosen, Gabriella D'Andrea, Maura Dickler, Mary E. Moynahan, Steven Sugarman, Weining Ma, Sujata Patil, Larry Norton, Alison L. Hannah, Clifford Hudis

Clin Cancer Res (2011) 17 (15): 5132–5139.

https://doi.org/10.1158/1078-0432.CCR-11-0072

Published: 31 July 2011

View article titled, HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Includes: Supplementary data

Journal Articles

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

Thomas Bachleitner-Hofmann, Mark Y. Sun, Chin-Tung Chen, David Liska, Zhaoshi Zeng, Agnes Viale, Adam B. Olshen, Martina Mittlboeck, James G. Christensen, Neal Rosen, David B. Solit, Martin R. Weiser

Clin Cancer Res (2011) 17 (1): 122–133.

https://doi.org/10.1158/1078-0432.CCR-10-0253

Published: 04 January 2011

View article titled, Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

Includes: Supplementary data

Journal Articles

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Maurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, Claudia Aura, José Jimenez, Pier Davide Angelini, Gertrudis Sánchez, Marta Guzman, Josep Lluis Parra, Catherine Ellis, Robert Gagnon, Maria Koehler, Henry Gomez, Charles Geyer, David Cameron, Joaquin Arribas, Neal Rosen, José Baselga

Clin Cancer Res (2010) 16 (9): 2688–2695.

https://doi.org/10.1158/1078-0432.CCR-09-3407

Published: 28 April 2010

View article titled, Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Includes: Supplementary data

Journal Articles

Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma

Kathryn E. O'Reilly, Melanie Warycha, Michael A. Davies, Vanessa Rodrik, Xi K. Zhou, Herman Yee, David Polsky, Anna C. Pavlick, Neal Rosen, Nina Bhardwaj, Gordon Mills, Iman Osman

Clin Cancer Res (2009) 15 (8): 2872–2878.

https://doi.org/10.1158/1078-0432.CCR-08-2336

Published: 15 April 2009

View article titled, Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma

Includes: Supplementary data

Journal Articles

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

David B. Solit, Iman Osman, David Polsky, Katherine S. Panageas, Adil Daud, James S. Goydos, Jerrold Teitcher, Jedd D. Wolchok, F. Joseph Germino, Susan E. Krown, Daniel Coit, Neal Rosen, Paul B. Chapman

Clin Cancer Res (2008) 14 (24): 8302–8307.

https://doi.org/10.1158/1078-0432.CCR-08-1002

Published: 15 December 2008

View article titled, Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

Includes: Supplementary data

Journal Articles

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Sarat Chandarlapaty, Ayana Sawai, Qing Ye, Anisa Scott, Melanie Silinski, Ken Huang, Pat Fadden, Jeff Partdrige, Steven Hall, Paul Steed, Larry Norton, Neal Rosen, David B. Solit

Clin Cancer Res (2008) 14 (1): 240–248.

https://doi.org/10.1158/1078-0432.CCR-07-1667

Published: 02 January 2008

View article titled, SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Journal Articles

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

David B. Solit, S. Percy Ivy, Catherine Kopil, Rachel Sikorski, Michael J. Morris, Susan F. Slovin, W. Kevin Kelly, Anthony DeLaCruz, Tracy Curley, Glenn Heller, Steven Larson, Lawrence Schwartz, Merrill J. Egorin, Neal Rosen, Howard I. Scher

Clin Cancer Res (2007) 13 (6): 1775–1782.

https://doi.org/10.1158/1078-0432.CCR-06-1863

Published: 15 March 2007

View article titled, Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

Journal Articles

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

David B. Solit, Yuhong She, Jose Lobo, Mark G. Kris, Howard I. Scher, Neal Rosen, Frank M. Sirotnak

Clin Cancer Res (2005) 11 (5): 1983–1989.

https://doi.org/10.1158/1078-0432.CCR-04-1347

Published: 08 March 2005

View article titled, Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

Journal Articles

A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants

David R. Huron, Mercedes E. Gorre, Alan J. Kraker, Charles L. Sawyers, Neal Rosen, Mark M. Moasser

Clin Cancer Res (2003) 9 (4): 1267–1273.

Published: 01 April 2003

View article titled, A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants

Journal Articles

17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/ neu and Inhibits the Growth of Prostate Cancer Xenografts

David B. Solit, Fuzhong F. Zheng, Maria Drobnjak, Pamela N. Münster, Brian Higgins, David Verbel, Glenn Heller, William Tong, Carlos Cordon-Cardo, David B. Agus, Howard I. Scher, Neal Rosen

Clin Cancer Res (2002) 8 (5): 986–993.

Published: 01 May 2002

View article titled, 17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/ neu and Inhibits the Growth of Prostate Cancer Xenografts

NARROW

Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets

A Phase I Study of Alpelisib in Combination with Trastuzumab and LJM716 in Patients with PIK3CA-Mutated HER2-Positive Metastatic Breast Cancer

KRAS^G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas

Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF-Mutant Metastatic Colorectal Cancer Patients

Abstract A22: Role of cap-dependent translation in response to upstream kinase-targeted therapy in colorectal cancer

PI3K Pathway Activation in High-Grade Ductal Carcinoma In Situ—Implications for Progression to Invasive Breast Carcinoma

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF^V600E/K-Mutated Melanoma

Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer

HSP90 Inhibition Is Effective in Breast Cancer: A Phase II Trial of Tanespimycin (17-AAG) Plus Trastuzumab in Patients with HER2-Positive Metastatic Breast Cancer Progressing on Trastuzumab

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET Inhibition

Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor

Phosphorylated 4E-BP1 Is Associated with Poor Survival in Melanoma

Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase–Dependent Cancers

Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

Pulsatile Administration of the Epidermal Growth Factor Receptor Inhibitor Gefitinib Is Significantly More Effective than Continuous Dosing for Sensitizing Tumors to Paclitaxel

A Novel Pyridopyrimidine Inhibitor of Abl Kinase Is a Picomolar Inhibitor of Bcr-abl-driven K562 Cells and Is Effective against STI571-resistant Bcr-abl Mutants

17-Allylamino-17-demethoxygeldanamycin Induces the Degradation of Androgen Receptor and HER-2/ neu and Inhibits the Growth of Prostate Cancer Xenografts

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only